ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a upgraded with a price target of $0.00 to $2.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.38, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 44.93% | Chardan Capital | → $2 | Upgrades | Neutral → Buy |
| 09/18/2023 | 30.43% | Citigroup | $2.1 → $1.8 | Maintains | Buy |
| 08/07/2023 | 262.32% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/04/2023 | 44.93% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 226.09% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 334.78% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 262.32% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 334.78% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 262.32% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 262.32% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 262.32% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | 8.7% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 44.93% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 44.93% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 44.93% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 81.16% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 262.32% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 479.71% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 479.71% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 189.86% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1276.81% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1204.35% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1349.28% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1349.28% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 2291.3% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2798.55% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/08/2023 | 44.93% | 查丹資本 | → 2 美元 | 升級 | 中性 → 買入 |
| 09/18/2023 | 30.43% | 花旗集團 | 2.1 美元 → 1.8 美元 | 維護 | 買 |
| 08/07/2023 | 262.32% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 08/04/2023 | 44.93% | 查丹資本 | → 2 美元 | 重申 | 中性 → 中性 |
| 05/17/2023 | 226.09% | 坎託·菲茨傑拉德 | 5 美元 → 4.5 美元 | 維護 | 超重 |
| 05/17/2023 | 334.78% | JMP 證券 | → 6 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 05/17/2023 | 262.32% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 03/30/2023 | 334.78% | JMP 證券 | → 6 美元 | 重申 | → 市場跑贏大盤 |
| 03/30/2023 | 262.32% | HC Wainwright & Co. | 1.5 美元 → 5 美元 | 維護 | 買 |
| 12/23/2022 | 262.32% | 雷蒙德·詹姆 | 2 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 2022 年 12 月 22 日 | 262.32% | 坎託·菲茨傑拉德 | 0.8 美元 → 5 美元 | 升級 | 中性 → 超重 |
| 08/15/2022 | 8.7% | HC Wainwright & Co. | $2 → 1.5 美元 | 維護 | 買 |
| 2022 年 12 月 8 日 | — | 查丹資本 | 降級 | 買入 → 中性 | |
| 2022 年 12 月 8 日 | 44.93% | 雷蒙德·詹姆 | → 2 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 05/09/2022 | 44.93% | HC Wainwright & Co. | 4 美元 → 2 美元 | 維護 | 買 |
| 2022 年 6 月 5 日 | 44.93% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 買 |
| 2022 年 4 月 14 日 | 81.16% | 查丹資本 | 8 美元 → 2.5 美元 | 維護 | 買 |
| 2022 年 4 月 14 日 | 262.32% | JMP 證券 | 8 美元 → 5 美元 | 維護 | 市場表現跑贏大盤 |
| 02/14/2022 | 479.71% | 查丹資本 | 18 美元 → 8 美元 | 維護 | 買 |
| 02/14/2022 | 479.71% | JMP 證券 | 29 美元 → 8 美元 | 維護 | 市場表現跑贏大盤 |
| 02/14/2022 | 189.86% | HC Wainwright & Co. | 20 美元 → 4 美元 | 維護 | 買 |
| 02/14/2022 | — | 雷蒙德·詹姆 | 降級 | 強勢買入 → 市場表現 | |
| 2022 年 1 月 2 日 | 1276.81% | 雷蒙德·詹姆 | → 19 美元 | 啓動覆蓋範圍開啓 | → 強勢買入 |
| 2021 年 9 月 8 日 | 1204.35% | 查丹資本 | 20 美元 → 18 美元 | 維護 | 買 |
| 05/03/2021 | 1349.28% | Stifel | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/11/2020 | 1349.28% | 查丹資本 | 25 美元 → 20 美元 | 維護 | 買 |
| 11/19/2019 | 2291.3% | 花旗集團 | 40 美元 → 33 美元 | 維護 | 買 |
| 11/14/2018 | 2798.55% | 坎託·菲茨傑拉德 | → 40 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for ProQR Therapeutics (PRQR)?
ProQR Therapeutics (PRQR) 的目標價格是多少？
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Chardan Capital on November 8, 2023. The analyst firm set a price target for $2.00 expecting PRQR to rise to within 12 months (a possible 44.93% upside). 11 analyst firms have reported ratings in the last year.
Chardan Capital於2023年11月8日公佈了ProQR Therapeutics（納斯達克股票代碼：PRQR）的最新目標股價。該分析公司將目標股價定爲2.00美元，預計PRQR將在12個月內升至12個月內（可能上漲44.93％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
分析師對proQR Therapeutics（PRQR）的最新評級是多少？
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Chardan Capital, and ProQR Therapeutics upgraded their buy rating.
ProQR Therapeutics（納斯達克股票代碼：PRQR）的最新分析師評級由Chardan Capital提供，ProQR Therapeutics上調了買入評級。
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
ProQR Therapeutics（PRQR）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與ProQR Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。ProQR Therapeutics的最新評級是在2023年11月8日公佈的，因此您應該預計下一個評級將在2024年11月8日左右公佈。
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
分析師對 proQR Therapeutics (PRQR) 的評級正確嗎？
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a upgraded with a price target of $0.00 to $2.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.38, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的ProQR Therapeutics（PRQR）評級已上調，目標股價爲0.00美元，至2.00美元。ProQR Therapeutics（PRQR）目前的交易價格爲1.38美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
